---
title: "Alumis Inc. (ALMS.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ALMS.US.md"
symbol: "ALMS.US"
name: "Alumis Inc."
industry: "制藥"
---

# Alumis Inc. (ALMS.US)

| Item | Detail |
|------|--------|
| Industry | 制藥 |
| Location | 美股市場 |
| Website | [www.alumis.com](https://www.alumis.com) |

## Company Profile

Alumis Inc.是一家臨床階段的生物制藥公司，專注于自身免疫性疾病藥物的開發和商業化。該公司的臨床資產包括 ESK-001，一種用于治療斑塊型銀屑病和系統性紅斑狼瘡的別構酪氨酸激酶 2（TYK2）抑制劑；以及 A-005，一種能夠穿透中樞神經系統的別構 TYK2 抑制劑，用于神經炎症和神經退行性疾病。它還開發幹擾素調節因子 5（IRF5）以解決免疫功能障礙。該公司之前被稱為 Esker Therapeutics, Inc

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-27T04:30:19.000Z

**Overall: C (0.59)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 54 / 187 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -2.67% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 9.51 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3.66B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 22.12M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -66.88% | E |
| Profit Margin | -1108.24% | E |
| Gross Margin | 100.00% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% | C |
| Net Profit YoY | -2.67% | C |
| Total Assets YoY | 18.29% | A |
| Net Assets YoY | 10.44% | B |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -9.02% | D |
| OCF YoY | 0.00% | C |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.05 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 21.16% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Alumis Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-66.88%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1108.24%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-2.67%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "18.29%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "10.44%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-9.02%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.05",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "21.16%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 禮來 (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | 羅氏(ADR) (US.RHHBY) | A | B | B | D | C | B |
| 04 | 阿斯利康 (US.AZN) | A | B | C | D | C | B |
| 05 | 諾華制藥 (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -14.92 | 197/257 | - | - | - |
| PB | 9.51 | 170/257 | 2.98 | 1.10 | 0.94 |
| PS (TTM) | 165.36 | 148/257 | 54.03 | 24.08 | 12.23 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-25T05:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 9 | 90% |
| Overweight | 1 | 10% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 29.39 |
| Highest Target | 50.00 |
| Lowest Target | 32.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ALMS.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ALMS.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ALMS.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.